Lyell Immunopharma Stock Widgets and Gadgets
| LYEL Stock | USD 9.12 0.17 1.83% |
| Intraday Equity Chart Quick Equity Feed Equity Search Quote Ticker Widgets Data Sheet |
Live Stock Ticker Example
- LYEL Lyell Immunopharma
- Latest Lyell Immunopharma Price Target Significantly Increased LYEL Stock News
- LYEL 9.12 -0.17
- Low 8.78
- High 9.4
- Volume 71.5 K
- Alpha 0.0189
- Beta 1.12
- Return On Equity -0.71
- Return On Asset -0.24
- Current Valuation (114.76 M)
- Shares Outstanding 14.81 M
- Shares Owned By Insiders 12.20 %
- Shares Owned By Institutions 66.33 %
- Number Of Shares Shorted 10.63 M
- Price To Earning 3.66 X
- Price To Book 0.41 X
- Price To Sales 2,116 X
- Revenue 61 K
- Gross Profit 65 K
- EBITDA (200.64 M)
- Net Income (342.99 M)
- Cash And Equivalents 655.56 M
- Cash Per Share 2.64 X
- Total Debt 58.97 M
- Debt To Equity 0.08 %
- Current Ratio 13.26 X
- Book Value Per Share 22.79 X
- Cash Flow From Operations (162.39 M)
- Short Ratio 16.43 X
- Earnings Per Share (25.00) X
- Price To Earnings To Growth 0.68 X
- Target Price 11.0
- Number Of Employees 300
- Beta -0.27
- Market Capitalization 137.57 M
- Total Asset 490.86 M
- Retained Earnings (1.35 B)
- Working Capital 325.81 M
- Net Asset 490.86 M
- Accumulation Distribution 4713.39
- Daily Balance Of Power (0.27)
- Rate Of Daily Change 0.98
- Day Median Price 9.09
- Day Typical Price 9.1
- Price Action Indicator (0.06)
- Period Momentum Indicator (0.17)
- Relative Strength Index 48.81
Market Snapshot Widget Example
DAX Index Germany | 23,649 0.64 | |
Taiwan Weighted Taiwan | 22,492 0.28 | |
PSI 20 Stock Portugal | 7,431 0.49 | |
CROBEX Croatia | 3,628 0.77 | |
Budapest SE Hungary | 97,715 0.12 | |
IDX 30 Jakarta Indonesia | 397.38 1.40 | |
ISEQ 20 Price Ireland | 1,888 0.48 | |
NYSE Comp USA | 20,256 0.84 | |
Tel Aviv 35 Israel | 2,905 0.81 | |
Coreshares Index Tracker South Afric | 1,219 0.66 | |
IPC MEXICO Mexico | 56,743 0.33 | |
Bursa Malaysia Construction Malaysia | 293.11 0.41 | |
IBEX 35 Index Spain | 13,816 0.03 | |
SP Merval Argentina | 1,000,000 0.00 | |
Austrian Traded Index Austria | 4,358 0.07 | |
SPASX Dividend Opportunities Australia | 1,829 0.07 | |
VN Index Vietnam | 1,366 0.08 | |
Bucharest BET-NG Romania | 1,345 0.45 | |
AMS Small Cap Netherlands | 1,506 1.50 | |
Oslo Exchange Mutual Norway | 1,560 0.22 | |
BEL Small Belgium | 8,831 0.03 | |
Basic Materials Brazil | 4,978 1.62 | |
Swiss Leader Price Switzerland | 1,948 0.08 | |
Fondo Mutuo ETF Chile | 1,615 0.55 | |
Athens General Comp Greece | 1,883 0.62 | |
Stock Exchange Of Thailand | 1,107 0.09 | |
PX Prague Stock Czech Repub | 2,130 0.48 | |
THE PHILIPPINE STOCK Philippines | 6,331 0.08 | |
WIG 30 Poland | 3,656 2.26 | |
BIST Electricity Turkey | 504.98 0.02 |
Investing Ideas
In addition to having Lyell Immunopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Thematic Opportunities
Explore Investment Opportunities
Compare Lyell Immunopharma
Compare Lyell Immunopharma To Peers
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.00) | Revenue Per Share | Quarterly Revenue Growth 1.333 | Return On Assets | Return On Equity |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.